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Ocimum basilicum L. or basilicum is a common culinary herb, used as a traditional
medicine for various medical conditions including HIV/AIDS and tuberculosis, in Africa.
The objective of this study was to evaluate the effect of methanol, ethanol, aqueous and
ethyl acetate extracts of the dried leaves and inflorescence of O. basilicum, on the activity
of cytochrome P450 enzymes (CYPs) CYP2B6 and 3A4, as well as esterase-mediated
metabolism of rifampicin to 25-O-desacetyl rifampicin (25ODESRIF). Human liver
microsomes (HLM) were used to evaluate inhibition and CYP2B6/3A4 mRNA
expression HepG2 assays were used to measure induction. Furthermore, the
phytoconstituents likely involved in causing the observed effect were analyzed using
biochemical tests and LC-MS. The aqueous andmethanolic extracts showed reversible and
time-dependent inhibition (TDI) of CYP2B6 with TDI-IC50s 33.35 mg/ml (IC50 shift-fold >1.5)
and 4.93 mg/ml (IC50 shift-fold >7) respectively, while the methanolic and ethanolic extracts
inhibited 25ODESRIF formation (IC50s 31 mg/ml, 8.94 mg/ml). In HepG2 assays, the
methanolic and ethanolic extracts moderately induced CYP2B6, 3A4 mRNA with 38%-,
28%-fold shift, and 22%-, 44%-fold shift respectively. LC-MS full scans identified phenols
rosmarinic acid [m/z 359 (M-H)-, approximately 2298 mg/L in aqueous extract] and caftaric
acid along with flavones salvigenin [m/z 329 (M+H)+, approximately 1855 mg/L in ethanolic
extract], eupatorin [m/z 345 (M+H)+, 668.772 mg/L in ethanolic extract], rutin [m/z 609 (M-
H)-] and isoquercetin [m/z 463 (M-H)-] and other compounds—linalool [m/z 153 (M-H)-],
hydroxyjasmonic acid [m/z 225 (M-H)-], eucommiol [m/z 187 (M-H)-] and trihydroxy
octadecenoic acid [m/z 329 (M-H)-, 530 mg/L in ethanolic extract]. The putative
gastrointestinal tract (GIT) concentration for all extracts was calculated as 2,400 mg/ml
and hepatic circulation concentrations were estimated at 805.68 mg/ml for the aqueous
extract, and 226.56 mg/ml for methanolic extract. Based on the putative GIT concentration,
estimated hepatic circulation concentration [I] and inhibition constant Ki, the predicted
percentile of inhibition in vivowas highest for the aqueous extract on CYP2B6 (96.7%). Thein.org April 2020 | Volume 11 | Article 5171
GRAPHICAL ABSTRACT
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Frontiers in Pharmacology | www.frontiersobservations indicated that O. basilicum extracts may have the potential to cause clinically
relevant herb-drug interactions (HDI) with CYP2B6 and rifampicin metabolism in vivo, if
sufficient hepatic concentrations are reached in humans.Keywords: herb-drug interactions, LC-MS, basil, phytoconstituents, CYP450, time-dependent inhibition,
HepG2, inductionin.org April 2020 | Volume 11 | Article 5172
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Kumar et al. Herb-Drug Interaction of Ocimum basilicumINTRODUCTION
Ocimum basilicum L. (Lamiaceae) or sweet basil is a popular
culinary and ornamental herb, used for its medicinal properties
in Asia and Africa. The herb is native to India, Southeast Asia,
New Guinea and many countries in Africa, and a famous
ingredient in Ayurveda, Unani and Siddha system of
traditional medicine. The distinct characteristic aroma,
chemical composition and biological activity of the basil
essential oil depend on factors such as morphological
variability, topography and other environmental factors
(Nurzynska-Wierdak et al., 2012). It is used as an Indian
traditional medicine in the supplementary treatment of
asthma, diabetes and stress (Duke, 2008). Ethnic communities
in Africa and India use whole basil plant decoctions in patients
with tuberculosis (TB) (Rai, 2016; Dzoyem et al., 2017). The
volatile oil of basil comprises of components such as eugenol
(Akgül, 1989), geraniol, eucalyptol, fenchone, and estragole
(Muráriková et al., 2017), some of these compounds being
used as a local antiseptic and anaesthetic (Jadhav et al., 2004).
Previous studies have shown anti-TB activity of the crude
methanolic extract from the aerial parts (leaves, fruits, and
flowers) of basil (Siddiqui et al., 2012). In vitro studies have
shown that phytocompounds in the oil have potent antioxidant,
antiviral, and antimicrobial properties, and have been tested in
cancer treatment (Chiang et al., 2005; Bozin et al., 2006;
Manosroi et al., 2006; de Almeida et al., 2007). Esters and
amides synthesized from dichloromethane extract of basil have
been tested in vitro using an HIV-1 Reverse Transcriptase (RT)-
associated RNase H inhibition assay; tetradecyl ferulate inhibited
RNase H with IC50 12.4 mM and N-oleylcaffeamide strongly
inhibited the RT-associated activity of ribonuclease H and DNA
polymerase (Sonar et al., 2017).
Due to the use of this herb as a common spice as well as its
availability in the pharmacies as a liquid/powder extract and pure
essential oils for various health conditions, there is a potential for
concomitant administration with conventional drugs, hence
potential for herb-drug interactions (HDI). The phytoconstituents
within the herbs can potentially inhibit or induce the activity of
drug-metabolizing enzymes and transport proteins. Recent studies
have examined the inhibitory and inducing effects of various West
African, Chinese, South American and Indian herbs and their
extracts or formulations, such as Uncaria tomentosa (Willd. ex
Schult.) DC. (Weiss, 2019), Astragalus mongholicus Bunge (Kumar
et al., 2018), Momordica charantia L. (Fasinu et al., 2017), and
Curcuma longa L. and Phyllanthus emblica L. (Shengule et al., 2018),
on cytochrome P450 activities.
Previous studies showed the inhibitory effect of the methanolic
extract of basil on the activity of CYP2D6, CYP3A4, CYP3A5, and
CYP3A7 (Nguyen et al., 2014). Another study using MROD assay
(7-methoxyresorufin dealkylation) showed the inhibitory effect of
methanol-dibutyl ether extract from basil on the CYP1A2
mediated metabolism of methoxyresorufin to its fluorescent
metabolite resorufin (Jeurissen et al., 2007). Other interactions
reported include the induction of CYP2A6, 2C9, 2D6 and 2E1 by
safrole and estragole present in basil extracts, to form carcinogenicFrontiers in Pharmacology | www.frontiersin.org 31′-hydroxy metabolites (Jeurissen et al., 2004; Jeurissen
et al., 2007).
Systematic review studies have reported the high HIV/TB-
burden in African countries where coinfected patients are treated
with efavirenz and rifampicin-isoniazid regimens (Atwine et al.,
2018). The current WHO TB-HIV treatment guideline for the
effective dosage of efavirenz in patients during concomitant
rifampicin-based anti-TB therapy is 600 mg/day; this being
confirmed in previous studies in the sub-Saharan Africa (Bhatt
et al., 2014; Habtewold et al., 2015). However, with the possibility
of drug-drug interactions involving CYP2B6 and 3A4, it is
necessary to analyze if the coadministration of basil in such
scenarios can cause clinically significant herb-drug interactions.
For example, artemisinin extract obtained from the Chinese herb
Artemisia annua L., used in malarial treatment and metabolized
by CYP2B6 and 3A4, has been studied to cause potential
toxicities in vitro when coadministered with drugs such as
orphenadrine (Hedrich et al., 2016), which could be attributed
to CYP2B6/3A4 inhibition and incomplete metabolism.
CYP2B6 predominantly metabolizes efavirenz to its primary
metabolite 8-hydroxy efavirenz with the involvement of CYP3A to a
lesser extent, and CYP2A6-mediated metabolism to 7-Hydroxy
efavirenz. CYP2B6 plays a critical role in efavirenz metabolism,
forming the secondary metabolite 8,14-dihydroxy efavirenz from 8-
hydroxy efavirenz (Ward et al., 2003). Previous studies have shown
the significance of various factors such as ethnicity and
pharmacogenetic variations (CYP2B6 alleles) in influencing the
efavirenz pharmacokinetics in HIV/AIDS patients in Africa
(Swart et al., 2012; Ngaimisi et al., 2013). CYP3A4 catalyzed
metabolism pathway devises a major route for elimination of
many drugs and the induction or the inhibition of its expression
by other drugs or herbs is often implicated in clinically significant
interactions. Many drug-drug interaction (DDI) studies related to
drug-resistant TB and TB/HIV co-infection analyzed the
involvement of CYP3A4 as a key enzyme (Kwara et al., 2010).
Research has been done to explore the effects of rifampicin as an
inducer in herb and drug-drug interaction studies; however the
effect of HDI on the b-esterase-mediated metabolism pathway of
rifampicin to 25-O-desacetyl rifampicin has not been investigated.
Assessing its metabolism profile and the potential of the herbs to
induce or inhibit the formation of 25-O-desacetyl rifampicin is
critical, because if the normal pharmacokinetics of this metabolism
pathway is affected, incomplete metabolism of rifampicinmay result
in toxicity and fatal poisoning (Cheng et al., 1988; Sridhar et al.,
2012). Case studies have reported reversible hepatic, renal damage
and fatal poising with the ingestion of 9–12 g and 14–15 g of
rifampicin (Plomp et al., 1981; Cheng et al., 1988; Marks et al.,
2009). The high burden of rifampicin toxicities among HIV/TB co-
infected patients (Gort et al., 1997; Yee et al., 2003) often contributes
to morbidity and mortality; anti-TB drug induced liver injury in
China being an example (Shang et al., 2011).
This research study investigated the relevant phyto-
compounds present in the dried leaves and inflorescence of O.
basilicum using various biochemical tests, LC-MS and their
interactions with CYP2B6, 3A4, and rifampicin metabolism (b-
esterases) in HLM and HepG2 cells. The potential clinicalApril 2020 | Volume 11 | Article 517
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the inhibitory potential of the extracts in the GIT.MATERIALS AND METHODS
Reagents and Chemicals
The biochemical tests were performed using the following reagents:
• Dilute ammonia solution (Hopkin and Williams, England).
• Vanillin reagent: 1% vanillin in 70% concentrated sulphuric
acid (BDH Chemicals, England).
• Wagner’s reagent: 2 g of iodine (BDH Chemicals, England)
and 6 g of potassium iodide (Merck, Germany) dissolved in
100 ml of water.
• Neutral ferric chloride solution, 0.1% ferric chloride solution
(Sigma-Aldrich, Steinheim, Germany).
• 10% Sodium hydroxide solution (BDH Chemicals, England).
• Magnesium solution (Hopkin and Williams, England).
• Glacial acetic acid, concentrated sulphuric acid (BDH
Chemicals, England), ferric chloride (Sigma-Aldrich,
Germany).
• Chloroform, acetic anhydride (BDH Chemicals, England).
Efavirenz, rifampicin, ticlopidine and nelfinavir mesylate
hydrate were obtained from Sigma-Aldrich (Steinheim,
Germany), while pure 8-hydroxy efavirenz, 25-O-desacetyl
rifampicin and neostigmine methyl sulphate were obtained
from Clearsynth Labs Ltd. (Mumbai, India).
HPLC-grade methanol (Sigma-Aldrich, Germany), ethanol
(Merck KGaA, Darmstadt, Germany), purified HPLC-grade
water (Adrona B30 purification systems, Adrona SIA, Latvia),
and ethyl acetate (BDH Chemicals, England) were used for the
extractions and LC-MS mobile phase solvents.
For the HLM inhibition assays, magnesium chloride, glucose-
6-phosphate sodium salt, glucose-6-phosphate dehydrogenase,
phosphate buffer solution 1 M, and b-nicotinamide adenine
dinucleotide phosphate hydrate (NADPH) were purchased
from Sigma-Aldrich (Steinheim, Germany). For the induction
assays, microtiter 96–well U–bottom plates from Tarsons
Products Pvt. Ltd., Kolkata, India were used. 25 cm2 cell
culture flasks were purchased from Corning® Inc. (New York,
US). MTT (thiazolyl blue tetrazolium bromide), phosphate
buffered saline pH 7.4 (PBS), nutrient mixture F-12 Ham,
EDTA, Dulbecco’s modified Eagle’s medium—high glucose
(DMEM), trypsin, and the antibiotics for cell culture were
purchased from HiMedia Laboratories (Mumbai, India).
Gibco™ Fetal bovine serum (FBS) was purchased from
Thermofisher Scientific (MA, USA). Tri-Xtract™ for the RNA
isolation was purchased from G-Biosciences Ltd. (MO, US).
Dimethyl sulfoxide (DMSO) was purchased from Finar Ltd.
(Gujarat, India).
Plant Material
The dried leaves and inflorescence of O. basilicum (Lamiaceae)
were obtained in powdered and packed form, from PharmaFrontiers in Pharmacology | www.frontiersin.org 4Germania, Benoni, South Africa (Certificate of Analysis# PFI-
2645/08/2014, country of origin—Egypt).
Preparation of Plant Extracts
The dried leaves and inflorescence of O. basilicum were weighed
(4 g) andextracted exhaustively after boiling with purified water
(Adrona B30, up to 500 ml for 9 days). Forthe other solvent
extractions, 4 g of the herb was added to methanol, ethanol and
ethyl acetate(HPLC grade), and extracted exhaustively using
mechanical agitation (up to 500 ml for 9 days). The extract
was filtered and evaporated at 50°C using a concentrator-freeze
drier (miVac, England) to complete dryness and stored in sealed
glass containers in a vacuum desiccator, at 2–4 °C. Percentage of
yield was calculated as per equation (2.3.1):
Extract  % yield = (W1=W2) 100 Eq: (2:3:1)
Where, W1 is net weight of basil extract in grams after
extraction and W2 is total weight of dried basil in grams taken
for extraction.
Human Liver Microsomes and HepG2
Cell Lines
The HLM assays were performed using H0630—pooled human
liver microsomes (mixed gender, protein concentration: 20 mg/
ml) obtained from Sekisui Xenotech LLC (Kansas, USA). HepG2
(human hepatocellular carcinoma cells) cell line was procured
from National Centre for Cell Sciences (NCCS), Cell Repository,
Pune, India.
Analytical Instrumentation Settings
LC-MS phytochemical fingerprinting analyses were performed
using Waters Synapt G2 Quadrupole time-of-flight (QTOF)
mass spectrometer (MS) connected to a Waters Acquity ultra-
performance liquid chromatograph (UPLC) (Waters, Milford,
MA, USA). Waters HSS T3, 2.1 × 100 mm, 1.7 mm column was
used for the separation. A cone voltage of 15 V for both positive
and negative mode ionizations, desolvation temperature of 275°C,
and desolvation gas at 650 L/h (Stander et al., 2017). Data were
acquired by scanning all extracts, from 150 to 1,500 m/z in
resolution mode as well as in MSE mode. In MSE mode two
channels of MS data were acquired, one used low collision energy
(4 V) and the second one at collision energy ramp in the range 40
−100 V, to obtain fragmentation data as well. Sodium formate was
used to calibrate the UPLC-MS and leucine enkaphalin was used
as reference mass (lock mass) for accuracy in mass determination;
Waters HSS T3, 2.1 × 100 mm, 1.7 mm column was used for
the separation.
For the HLM assay sample analyses, Waters Alliance 2695
HPLC system coupled with 2996 PDA detector was used. A C-18
Phenomenex-Evo column (150 x 2.6 mm, 3.5 mm) and a C-18
Phenomenex Luna column (150 x 4.6 mm, 5 mm) was used for
separating efavirenz and 8-hydroxy efavirenz, and rifampicin
and its metabolite, respectively. PDA wavelength was set at 245
nm for efavirenz assay sample analyses and 254 n for rifampicin
assay sample analyses. The gradient solvents elution programApril 2020 | Volume 11 | Article 517
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11.5/10 (Varghese et al., 2014; Kumar et al., 2017).
AE-series inverted microscope (Motic Asia, Hong Kong) was
used for tissue culture inspection. BioTek Epoch automated
microplate reader with Gen5 2005 software v1.10.8 (BioTek
Instruments, Inc. USA) was used for plate incubations and
readings. Polymerase chain reactions were done using the MJ
mini thermocycler (Bio Rad, Hercules, CA, USA).
Data Analysis
Non-linear regression graph plots for determining the IC50 and
statistical analyses were performed using GraphPad Software Inc.
(San Diego, CA; www.graphpad.com) Prism version 5.00 for
Windows, was used.
For gel electrophoresis applications, inGenius—gel
documentation system comprising of GeneTools analysis
software (Syngene, MD, USA) was used for digital imaging and
relative sample expression levels.Biochemical Phyto-Profiling
The following standard methodologies were followed for
biochemical tests (Harborne, 1973; Raaman, 2006; Iqbal
et al., 2015):
1. Test for alkaloidsFrontiera. Harborne Test
About 170 ml of dilute ammonia solution was added
to 200 ml of test solution of each basil extract followed
by addition of few drops of concentrated sulphuric
acid. Formation of yellow coloration indicated the
presence of alkaloids.
b. Wagner’s Test
To 500 ml of plant extract solution, equal amount of
Wagner’s reagent was added. The test result was
observed. Formation of reddish-brown coloration
ascertained the presence of alkaloids.2. Test for saponins
About 200 ml of the plant extract was mixed with 170 ml of
pure distilled water and shaken vigorously for a stable
persistent froth, which indicated the presence of saponins.
3. Test for phenols
To 200 ml of the plant extract solution, 150 ml of neutral
ferric chloride solution was added. Formation of greenish
colour showed the presence of polyphenols.
4. Test for tannins
To 200 ml of the plant extract solution, 150 ml of 0.1%
ferric chloride was added and observed for the formation of a
bluish-black precipitate, which indicated the presence of
tannins in the extract.
5. Test for glycosides (Keller-Kiliani Test)
To 200 ml of the plant extract solution, 150 ml of glacial
acetic acid was added. To the resultant, a pinch of ferric
chloride along with 100 ml of sulphuric acid was added.
Formation of a prominent brown ring showed the presence of
glycosides.
6. Test for terpenoids (Salkowski Test)s in Pharmacology | www.frontiersin.org 5About 200 ml of the plant extract was mixed with 75 ml of
chloroform, and 125 ml of concentrated sulphuric acid was
carefully added from the sides of the test-tube to form a
reddish-brown layer, which indicated the presence of
terpenoids in the plant extract.
7. Test for flavonoids
To 200 ml of the plant extract solution, equal amount of
Vanillin reagent was added. Formation of reddish-brown
colour precipitate indicated the presence of flavonoids in
the extract.
8. Test for steroids (Leibermann-Burchard Test)
To 200 ml plant extract solution, 150 ml of chloroform was
added. Then 3-4 drops of acetic anhydride and three drops of
concentrated sulphuric acid were added. Formation of a
dark-bluish precipitate confirmed the presence of
phytosterols in the extract.
9. Test for coumarins
To 200 ml plant sample extract solution, equal quantity of
10% sodium hydroxide solution was added and heated at 100 °C
for 5 min. Formation of yellow color indicated the presence of
coumarins in the plant extract.Inhibition Assays
Validation of HLM Assays for Efavirenz
and Rifampicin
Satisfactory separation of the drug, its metabolite and the
internal standard was achieved using gradient elution (Figure 1).
Method optimization was achieved by modifying various run
parameters such as change in gradient elution and, inner column
diameter (2.6 and 4.6mm), length (100, 150, and 250mm), and
particle size (3.5 mm and 5 mm).
A linear response was obtained in the concentration range 0–
200 mM for both efavirenz and its metabolite (R2 = 0.9930).
LLOD and LLOQ were calculated at 7.57 mM and 22.95 mM for
efavirenz and 7.99 mM and 24.24 mM for 8-hydroxy efavirenz,
respectively. The peak area of the internal standard neostigmine
was relatively constant for all time-point incubations. For the
rifampicin method, a linear response was obtained in the
concentration range 0–200 mM for both rifampicin and 25-O-
desacetyl rifampicin (R2 = 0.9950). LLOD and LLOQ were
calculated at 5.86 mM and 17.75 mM for rifampicin and 7.78
mM and 23.57 mM for 25-O-desacetyl rifampicin, respectively
(Table 1). Linearity was established for both time-variant HLM
assays with R2 = 0.9918 (Varghese et al., 2014; Kumar
et al., 2017).
Four incubation time points (15, 30, 45, and 60 min, in
triplicates) were selected for the in vitro human liver microsomal
incubation assays for efavirenz and rifampicin. The metabolites
for both drugs were detected, separated and quantified (peak
area) along with the internal standard neostigmine, at consistent
retention times using the above method parameters; the peak
area of neostigmine for the assays were relatively constant
(Figure 1A, B). Linearity was attained for the 15–60 min time-
point incubations based on the ratio of the metabolite to the
internal standard, with R2 = 0.9934 for efavirenz and R2 = 0.9901
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Frontiers in Pharmacology | www.frontiersin.org 7percentage of remaining activity was expressed as in the equation
below (equation 2.8.3.1):
% remaining activity
= (Test − test control)=(Control − control blank) 100%
Eq: (2:8:3:1)
A concentration range of 1–200 mg/ml of each active basil
extract (six-point screening), in triplicates, was used to determineA B
C D
FIGURE 2 | (A) Standard calibration curves for pure EFV and E8H standards; (B) HLM time variant incubation assay linearity showing the ratio of E8H to NEO, for
the specific time of incubation (15, 30, 45, and 60 min), (C) Standard calibration curves for pure RIF and 25ODESRIF standards (D); HLM time variant incubation
assay linearity showing the ratio of 25ODESRIF to NEO, for the specific time of incubation (15, 30, 45, and 60 min). EFV, efavirenz; E8H, 8-hydroxy efavirenz; NEO,
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CYP2B6 EFV 15.08 0.3576 0.0240
b-esterases RIF 48.23 1.2330 0.0260*Vmax, pmol/min/mg protein or pmol/min/pmol P450; Km, mM; CLint, ml/min/mg protein or
ml/min/pmol P450 (Kumar et al., 2017; Kumar et al., 2018; Kumar et al., 2019).April 2020 | Volume 11 | Article 517
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concentration ranges 1–100 mM (0–66.30 mg/ml) to determine
their IC50 values. The percentage of remaining activity was
plotted on GraphPad prism against the log-transformed
concentrations of the herbal extract or the positive control,
using non-linear dose-response inhibition regression analysis
to obtain the sigmoidal curves for the IC50s.
For the TDI assays, the active basil extracts were pre-
incubated with HLM and buffer (90 ml) and the co-factors
(reaction master mix, 100 ml) at 37°C for 30 min prior to
addition of 10 ml of the substrate (15 mM efavirenz or 48
mM rifampicin).
The TDI fold-shift was calculated using the ratio of the IC50s
of the normal assay IC50(-) to that of the pre-incubation assay
IC50(+), with NADPH (equation 2.8.3.2).
TDIfold-shift = normal assayIC50( − )=pre-incubation assayIC50( + )
Eq: (2:8:3:2)
Extracts with fold shifts ≥1.5 were classified positive for TDI
(Nomeir et al., 2004).
The dose-response curves in sections Preparation of Plant
Extracts and Human Liver Microsomes and HepG2 Cell Lines
represent the IC50 (mM) calculated using non-linear regression
(dose-response inhibition) v/s the actual IC50 plot curve-fit.Hepatic Blood Concentrations—Prediction on
Inhibition Percentage
The concentrations of each basil extract in the GIT and in
hepatic blood were estimated using the percentage yield (% W/
W, section Reagents and Chemicals) on the basis of a basic model
(F.D.A., 2017) where the maximal unbound plasma
concentration of the interacting herb [I] was calculated using
an estimated available GIT fluid of 250 ml (Mudie et al., 2014;
Thomford et al., 2016) and the recommended single dosage of
each extract obtained from various online sources (https://www.
drugs.com; https://draxe.com/; http://naturimedica.com) and the
label insert instructions obtained for the crude basil extracts
obtained from Pharma Germania, Benoni (equation 2.8.4.1).
Putative GIT Conc: (mg=ml)
= (Recommended single dose(mg=ml))=250 Eq: (2:8:4:1)
The available hepatic blood concentration of the extract [I]
was calculated using the putative GIT concentration value, based
on the equation (2.8.4.2).
Estimated Hep: Blood Conc:  ½I (mg=ml)
= (% yield*Putative GIT Conc: mg=ml))=100 Eq: (2:8:4:2)
The inhibition constant (Ki) for each extract was calculated
based on the IC50 values on the assumption that most
documented CYP inhibitions are competitive, as per the
following equation (2.8.4.3):Frontiers in Pharmacology | www.frontiersin.org 8IC50 = Ki(1 + ½S=Km),  when ½S = Km,  Ki = IC50=2
Eq: (2:8:4:3)
S and Km values denote the substrate concentration used in
this study and the affinity constant for the metabolic activity,
respectively [15]. Likely hepatic HDI predictions for the basil
extracts were assessed and evaluated based on comparison of the
estimated concentration hepatic blood to the IC50 value for each
extract and the predicted percentage of inhibition was calculated
using the inhibitory concentration [I] as per the following
equation (2.8.4.4).
Predicted  %  inhibition  = (½I=(½I + Ki))*100 Eq: (2:8:4:4)
The herbs were ranked for their potential risk in causing HDI
based on the inhibitory potency ([I]/Ki inhibitory ratio).
According to the FDA guidelines, [I]/Ki > 1.0 is correlated to
high risk of potential DDI, [I]/Ki=0.1–1 is correlated to
intermediate risk for DDI and [I]/Ki < 0.1 is unlikely to cause
any significant interactions (Prueksaritanont et al., 2013). This
study did not use static and dynamic mechanistic models to
evaluate the plasma concentration-time curve ratio (AUCR) for
the target drugs in the presence of the herbal extracts, as
recommended in the FDA clinical pharmacology guidelines
(F.D.A., 2017).
Induction Assays
Cytotoxicity Testing and Determination of CC50
Stock solution of each basil extract was prepared in DMEM
medium supplemented with 2% inactivated FBS (10% w/v
concentration) and filtered using 0.22 μm syringe filter. Serial
two-fold dilutions were prepared from this for carrying out the
cytotoxicity studies. HepG2 cells were cultured in DMEM
supplemented with 10% inactivated FBS, penicillin (100 IU/
ml), streptomycin (100 mg/ml) and amphotericin B (5 mg/ml)
in a humidified atmosphere (5% CO2) at 37°C until confluency
was attained (Freimoser et al., 1999).
Cytotoxicity of the plant extracts was evaluated based on the
method described in a previous study on Plectranthus barbatus
Andrews (Nagarajappa et al., 2016). In brief, HepG2 cell
suspension was added to 96-well microtitre plate and after
24 h, the supernatant was flicked off, the monolayer formed
was washed with medium and 100 ml of each extract was added;
the plates were incubated in 5% CO2 atmosphere at 37°C for 72
h. Post this, the solution in each well was discarded and 50 ml of
tetrazolium dye (MTT) in PBS was added; plates were incubated
for 3 h. Post this, 100 ml iso-propanol was added and absorbance
was measured at 540 nm using plate reader. The growth
inhibition percentage was calculated as per the following
equation (2.9.1.1):
% growth inhibition = (Controlabsorbance
− testabsorbance)=Controlabsorbance  100 Eq: (2:9:1:1)
The dose-response curves against cell lines were used to
determine the half-cytotoxicity concentration (CC50) (Tukappa
et al., 2015).April 2020 | Volume 11 | Article 517
Kumar et al. Herb-Drug Interaction of Ocimum basilicummRNA Expression for CYP2B6 and 3A4
CC50 concentration of each extract was added to 60 mm
petridish comprising of the HepG2 cells cultured in DMEM
medium, FBS and amphotericin (48 h) and incubated for 24 h.
Total cellular RNA was isolated from the untreated (control) and
treated cells using Tri-Xtract™ as per the protocol provided by
the manufacturer (G-Biosciences Ltd). cDNA was synthesized
from each isolated RNA by reverse transcriptase kit (Thermo
Scientific Ltd. protocol). Primers for CYP3A4 and CYP2B6 were
selected as per a method developed previously for analysing the
modulation of CYPs (Park et al., 2009). 50 ml of the reaction
mixture (1x cDNA synthesis buffer, dithiothreitol (0.5 M),
RiboLock RNAse inhibitor (20 U), deoxynucleotide mix (1.6
mM), oligo dT (100 ng), reverse transcriptase (25 U), and total
RNA) was subjected to PCR for amplification of hepatic cells.
cDNAs using specifically designed primers (procured from
Eurofins, India) were used. The house keeping gene
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was co-
amplified with each reaction as internal control. Rifampicin (50
mM) and dexamethasone (10 mM) were used as positive controls
for CYP3A4 and CYP2B6, respectively (Nagarajappa et al.,
2016). For CYP3A4 oligo dT primer was used for first strand
synthesis and for second strand synthesis, 5′ ATTCAGCAAGA
AGAACAAGGACA 3′ and 5′ TGGTGTTCTCAGGCACAGAT
3′ were used as the forward and reverse primers, respectively. For
2B6, oligo dT primer was used for first strand synthesis and for
second strand synthesis, 5′ATGGGGCACTGAAAAAGACTGA
3′ and 5′ AGAGGCGGGGACACTGAATGAC 3′ were used as
the forward and reverse primers, respectively.
The amplified samples were further analyzed using agarose
gel electrophoresis. The gel was further developed using UV
illumination-digital imaging, and Syngene inGenius
documentation system and GeneTools analysis software was
used for calculating the expression levels per sample; one-way
analysis of variance, followed by Dunnett’s multiple comparison
tests, by fixing the significance level at p < 0.05, p < 0.01 and p <
0.001 was used (Nagarajappa et al., 2016).
LC-MS Conditions: Phyto-Profiling
Stock solutions were prepared by adding 8-10 mg of each extract
to 1 ml of 50% methanol in water containing 2% formic acid,
followed by dissolution in an ultrasonic bath (0.5 Hz, Integral
Systems, RSA) for 20 min at room temperature. The extracts
were then centrifuged and supernatants were analyzed for
phytocomposition. The reference standards quercetin and
gallic acid (Vallverdú-Queralt et al., 2015; Ramos et al., 2017)
were prepared in cocktail stock solutions with concentration of
200 mg/L of each standard. 2 ml of each extract was injected into
the LC-MS prepped with a mobile phase comprising of 0.1%
formic acid (solvent A) and acetonitrile containing 0.1% formic
acid as solvent B. A flow rate of 0.3 ml min−1, was maintained for
gradient elution starting with 100% solvent A for 1 min, which
was linearly changed to 28% B over 22 min, then changed to 40%
B over 50 seconds followed by a 1.5 min wash step with 100%
solvent B, and finally re-equilibration (to initial conditions) for 4
min. The column temperature was maintained at 55°C. The PDA
wavelength range was set between 230 and 600 nm.Frontiers in Pharmacology | www.frontiersin.org 9The methods were tested for accuracy and linearity. A linear
response was obtained for quercetin for the positive mode run, in
the range of 200.000–6.250 mg/l (R2 = 0.9900) (Figure 4). This
concentration range was selected to identify and compare the
peak-retention factors and m/z of the extract with the reference
standard, along with reasonable approximations of the relative
amounts of the identified peaks using the standard calibration
curve of quercetin. The calibration curve showed slight non-
linearity at higher concentrations (200 mg/l) for both standards
in the negative mode. A quadratic linear curve fitting model was
used for quercetin (R2 = 0.9879) for relative quantification of the
unknown phytocompounds, based on the peak area (response)
for the concentration range used (200.000–6.250 mg/L) whereas
a linear fit model was used for gallic acid (R2 = 0.9680) since the
peak area (response) was less for low concentrations.
Tentative identification of the phytocompounds was done
based on the following parameters (Stander et al., 2017):
• Accurate masses
• m/z transitions (MS/MS fragments)
• UV maxima
• Relative retention times and comparison with literature
review on matching compounds
Online mass spectral repositories such as Metlin Scripps
(https://metlin.scripps.edu/), MassBank online Spectral
Database (https://massbank.eu/MassBank/), NIST standard
reference data online webbook library (http://webbook.nist.
gov/chemistry/mw-ser.html), and Pubchem chemistry database
(https://pubchem.ncbi.nlm.nih.gov).RESULTS
Extraction and Yield of Basil Extracts
for Bioassays
Exhaustive extraction of basil herb was done with water,
methanol, ethanol and ethyl acetate; per 4g of the dried basil
extract, highest solvent yield was observed in the aqueous extract
(BasilAq) of basil with 33.57%, followed by the methanol solvent
(BasilMeOH) at 9.44% and ethyl acetate (BasilEtOAc) at 4.93%.
Ethanol extract (BasilEtOH) yield was the least with 2.94%
(Table 3).
Biochemical Phytoprofiling
The biochemical qualitative tests confirmed the presence of
phytoconstituents such as alkaloids, glycosides, terpenoids,
phenols, coumarins and flavonoids within the extracts;
precipitate formation and color intensity formed the basis for
the chemical tests (Table 4). All four basil extracts showed
positive to the detection tests for all compounds, coumarins
and phytosteroids present in trace amounts.
HLM Screening and IC50 Assays
HLM assays were used to evaluate the inhibitory effect of basil
extracts on CYP2B6 and rifampicin metabolism. The aqueousApril 2020 | Volume 11 | Article 517
Kumar et al. Herb-Drug Interaction of Ocimum basilicumand methanolic extracts reduced CYP2B6 activity by less than
50% at 200 mg/ml concentrations, whereas the positive control
ticlopidine reduced the activity to 50% at 19.78 mg/ml. For the
two-point screening against rifampicin metabolism, except for
the aqueous extract, all extracts inhibited the formation of 25-O-
desacetyl rifampicin; ethanol extract reduced the activity to less
than 40%. The positive control nelfinavir reduced the activity by
30% at 49.79 mg/ml concentrations (Figure 5).
For CYP2B6 IC50 screening of the extracts, the methanolic
extract inhibited the efavirenz metabolism pathway with an IC50
value 36.07 mg/ml, while the aqueous extract had an IC50 value of
54.96 mg/ml (Figures 6A–C). The positive control ticlopidine
had an IC50 of 14.47 mg/ml (54.88 mM) when tested for inhibition
activity, in a concentration range of 0–26.38 mg/ml (0–100 mM).Frontiers in Pharmacology | www.frontiersin.org 10The ethanolic extract inhibited the rifampicin metabolism
pathway, with the lowest IC50 value 8.94 mg/ml, while the
methanolic extract exhibited an IC50 value of 31 mg/ml. The
positive control nelfinavir inhibited the formation of 25-O-
desacetyl rifampicin with an IC50 value of 5.44 mg/ml (Figures
6D–F).TDI IC50 Fold Shift Determination
Time-dependent inhibition (TDI) is the irreversible inhibition of
the enzyme activity, where the potency of the inhibitor increases
on prolonged exposure to the CYPs during pre-incubation time
period. For basil extracts the TDI was assessed by pre-incubation
with NADPH for 30 min (Stresser et al., 2014). The aqueous and
methanolic extracts exhibited TDI of CYP2B6 activity with IC50
values 33.35 and 4.93 mg/ml, respectively. However, none of the
extracts demonstrated TDI effects against the rifampicin
metabolism pathway; for the ethanolic extract, the IC50 shift
observed was > 100 mg/ml. Comparatively both positive controls
showed clear TDI with IC50 shifts to 9.63 mg/ml for ticlopidine
against CYP2B6, and 3.63 mg/ml for nelfinavir against rifampicin
pathway (Figure 7).
The IC50 shift-fold was calculated as the ratio of the co-
incubation IC50(-) to the pre-incubation IC50(+) with NADPH,
for each extract and the controls. The aqueous and methanolicApril 2020 | Volume 11 | Article 517A B
C
FIGURE 4 | (A) Concentration range linearity for quercetin (R2 = 0.9879) in positive mode LC-MS scan, (B, C)—regression line-fit concentration range linearity for
gallic acid & quercetin (R2 = 0.9441 & 0.9678) in LC-MS negative mode scans, respectively.
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± 378 mg, 9.44% ± 118 mg,
2.94%
± 193 mg, 4.83%±mg - approximate, negating the residual amount of extract retained in the glass tubes
after scraping.
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Frontiers in Pharmacology | www.frontiersin.org 11extracts showed positive TDI for CYP2B6; the methanolic extract
exhibited strong TDI with 7.4-fold increase in the IC50. Both
positive controls ticlopidine and nelfinavir demonstrated clear
TDI with the IC50 shift-fold >1.5 (Figure 8).HEPG2 Induction Assays
For the MTT assays, all basil extracts were screened for in vitro
cytotoxicity levels against HepG2 cells, by exposing the cells to
various concentrations of each extract (1,000.00–31.25 mg/ml).
The concentration of the test extract needed to inhibit cell
growth by 50%–CC50 values were calculated for the four basil
extracts as illustrated in Table 5. The ethanolic extract had the
lowest CC50 of 70.58 ± 0.83 mg/ml in HepG2 cells (Table 5).
Based on the CC50 values, the inducing effect of each extract
on mRNA expression of the HepG2 cells was determined using
RT-PCR and AGE techniques. The expression levels of CYP2B6
and CYP3A4 are depicted as arbitrary units normalized to
(GAPDH) mRNA (Figure 9).
For CYP3A4, the positive control rifampicin (50 mM) showed
significant fold induction (p < 0.001) compared to the cell control
(CC). None of the extracts showed 2-fold induction on CYP3A4
mRNA expression indicating that they were only moderate
inducers. All basil extracts induced CYP3A4, with the
methanolic extract showing 22%-fold response increase and
ethanolic extract at 44%. However, none of the extracts induced
both CYPs over 2-fold, indicating that the phytomolecules present
in these extracts are not strong inducers of CYP2B6 and 3A4.
Based on the results observed in the mRNA expression assays in
HepG2 cells, it was concluded that CYP3A4 was more inducible
by basil extracts compared to CYP2B6 (Figure 10A).
Dexamethasone (10 mM), the positive control against
CYP2B6, showed significant fold induction (p < 0.001) when
compared to the cell control (CC, no inducer). In comparison,
the extracts showed less than 2-fold induction and therefore were
only moderate inducers. The methanolic and ethanolic extracts
moderately induced CYP2B6 mRNA with 38%- and 28%-fold
shifts respectively (Figure 10B).TABLE 4 | Biochemical qualitative profile of basil extracts.
Sl # Phyto
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The identified phytocompounds (acidic and non-acidic
compounds) were relatively quantified using gallic acid and
quercetin as reference standards. Gallic acid calibration was
determined in negative scan mode in the MS since most of theFrontiers in Pharmacology | www.frontiersin.org 12acidic compounds were detected in the same scan mode. Each
negative scan was performed for 29 min, whereas the positive
scan spanned 15 min (Figures 11A, B).
In the negative scan mode, the major observations noted for




FIGURE 6 | Dose-response curves of basil extracts (with IC50s) for (A) aqueous extract (54.96 mg/ml), (B) methanolic extract (36.07 mg/ml), and positive control (C)
ticlopidine (14.47 mg/ml, 54.88 mM) against percentage remaining activity of CYP2B6 with efavirenz as the substrate. Figures (D) methanolic extract (31 mg/ml), (E)
ethanolic extract (8.94 mg/ml), and positive control (F) nelfinavir (5.44 mg/ml, 9.59 mM) represent the IC50 dose-response curves of basil extracts against percentage
remaining activity of rifampicin metabolism. The IC50 is calculated as log(X) against Y.
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Kumar et al. Herb-Drug Interaction of Ocimum basilicum1. Rosmarinic acid, a polyphenol was the most prominent peak
in all extracts of basil (Figure 12A). It had a retention time of
21.65 min at m/z 359 (M-H)- and detection wavelength of
329nm on the PDA (Figure 12A). The product ions were
identified at m/z 161, 133, 135, 179, and 197 (Figure 11B).
2. The flavone salvigenin (5-Hydroxy-6,7,4′-trimethoxyflavone)
was prominentlyobserved in the extracts, at retention time
24.36 min and m/z 327(M-H)-, with product ions at m/z
116.9, 205, 215, 277 and 311 (Figure 12B).
3. Acidic compounds such as tartaric, isocitric, caftaric and
chicoric acids were prominently observed in the aqueous
extract at m/z 149, 191, 311, and 473, at wavelengths 230 nm
for the first two and 328–329 nm for the latter two
compounds (Figures 12C–E).Frontiers in Pharmacology | www.frontiersin.org 134. Rutin, a major flavonoid, was observed only in the
methanolic extract at m/z 609 (M-H)- with products ions at
m/z 151, 255, 271, 300 and 301 (Figure 12F).
5. Apigenin-7-O-glucoside or apigetrin (also known as
cosmosiin), a flavonoid-7-O-glycoside, was detected in the
ethanolic extract with a retention time 14.76 min andm/z 431
(M-H)-.
6. Other significant compounds detected in the extracts were
eucommiol [m/z 187 (M-H)-], 12-hydroxyjasmonic acid [m/z
225 (M-H)-], trans-ocimene oxide [m/z 137 (M-H)-], and
medioresinol [m/z 387 (M-H)-].
In the positive mode MS scans (Figure 11B), the major
phytocompounds detected (Table 7) in the extracts included:A B
C D
E F
FIGURE 7 | Dose-response curves of basil extracts (with TDI IC50s) for (A) aqueous extract (33.35 mg/ml), (B) methanolic extract (4.93 mg/ml), and positive control (E)
ticlopidine (9.63 mg/ml, 36.51 mM) against percentage remaining activity of CYP2B6 (efavirenz as substrate) and (C) methanolic extract (> 100 mg/ml), (D) ethanolic extract
(75.76 mg/ml) and, (F) positive control nelfinavir (3.63 mg/ml, 6.39 mM) against percentage remaining activity of rifampicin metabolism. The TDI IC50 is calculated as log(X)
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Kumar et al. Herb-Drug Interaction of Ocimum basilicum1. Salvigenin (5-Hydroxy-6,7,4′-trimethoxyflavone)—the most
prominent peak in the methanol and ethanolic extracts, with
a retention time of 7.32 min at m/z 329 (M+H)+ and PDA
detection wavelength 230 nm (Figure 12B).
2. 2,6-Pyridinedicarboxylic acid, nonyl phenethyl ester [at m/z
398 (M+H)+] was detected in all the extracts with product
ions m/z 149, 240, and 266 (Figure 12H).
3. The flavone eupa to r in [3 ′ , 5 -d ihyd roxy -4 ′ , 6 , 7 -
trimethoxyflavone, m/z 345 (M+H)+] (Figure 12G) and the
aromatic lactone furan-2(3H)-one complex [m/z 311 (MFrontiers in Pharmacology | www.frontiersin.org 14+H)+] were the other major compounds identified, at
retention times 6.42 and 6.91 min, respectively.
The identified compounds were quantified (in mg/L
equivalent units of gallic acid/quercetin) relative to the linear
calibration curve of the reference standards (Table 8).
Salvigenin concentration was highest in the ethanolic extract
(1854.916 mg/L), followed by the fatty acid trihydroxy octadecenoic
acid (530.474 mg/L), the flavone eupatorin (668.772 mg/L) and
caffeic acid (580.949 mg/L). Rosmarinic acid was predominantly
present in the aqueous extract (2298.037 mg/L), along with isocitric
(999.946 mg/L), tartaric acid (798.347 mg/L), chicoric (496.228 mg/
L), and caftaric acids (545.019 mg/L).
Estimated Hepatic Blood Concentration of
the Extracts
The putative GIT concentration for the aqueous, methanolic and
ethanolic extracts was 2,400 mg/ml (refer section IC50 and TDI
Assays for formula). For a single recommended dose of 600 mg of
basil extract, the available hepatic blood concentration [I] was
estimated at 805.68 mg/ml for the aqueous extract against
CYP2B6, 226.56 mg/ml for the methanolic extract against
CYP2B6 and rifampicin metabolism, and 70.56 mg/ml for the
ethanolic extract against rifampicin pathway (Table 9). The
inhibitory potency [I]/Ki was >1.0 for all the extracts exhibiting
their likely potential of causing HDI. The predicted in vivo
inhibition percentiles were at 96.70% for the aqueous extract,
94.04% for the ethanolic extract and 92.62–93.60% for the
methanolic extract. However other factors such as AUC ratio of
the drugs, first order absorption rate Ka, fraction of systemic
clearance of the substrate Fm, elimination rate, CLint intrinsic
clearance, and the fraction absorbed after oral administration Fa
have not been considered in this prediction model (F.D.A., 2017).DISCUSSION
Traditional health practitioners often prepare herbal
formulations using tea infusions and overnight incubations
with alcoholic beverages such as brandy (Thring and Weitz,
2006). Hence aqueous and ethanolic extractions of basil were
selected for this study. Higher pharmacological activity is
generally observed in methanolic, ethanolic, and ethyl acetateFIGURE 8 | TDI Shift-fold plots. Bars represent the ratio of co-incubation
IC50(-) values for the extracts to the pre-incubation IC50(+) values with
NADPH, for basil extracts. Ticlopidine (TICL) and nelfinavir (NELF) were
positive controls for CYP2B6 and rifampicin pathway, respectively.
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BBasllM,OH FIGURE 9 | Relative CYP3A4 and CYP2B6 mRNA expressions by CC,
rifampicin, dexamethasone and basil extracts on agarose gel; relative
expression of GAPDH mRNA on agarose gel for normalization.TABLE 5 | Concentration of each basil extract that causes 50% cytotoxicity in
HepG2 cells (CC50).













































320.18 ± 2.13#Values are represented as mean ± SD (n = 3). CC50 calculated as the mean ± SD of
cytotoxicity % values on HepG2 cells at concentration range 1000–31.25 µg/ml for each
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Kumar et al. Herb-Drug Interaction of Ocimum basilicumextractions (Dhanani et al., 2017). Qualitative analysis is a
precursor to analytical fingerprinting of herbal constituents. As
per this study, high intensity of flavonoids, phenols, alkaloids,
terpenoids, and glycosides were observed in the extracts, some of
these compounds being potentially responsible for the aromatic
nature of basil oil (Loughrin and Kasperbauer, 2003) and its
potential to cause significant interaction with the CYPs. Previous
studies have shown the presence of triterpenoid saponins (Habib
et al., 2016), alkaloids, anthraquinones, saponins, and flavonoids
in the methanolic extract as well as glycosides, phenols,
phlobatatannins, tannins, and terpenoids in the aqueous
extract (Fakhroo and Sreerama, 2016). In this study more
compounds such as phytosteroids and coumarins were also
detected, especially in the ethyl acetate extract.
In the HLM screening, except for the aqueous extract
(affected only RIF metabolism), all extracts of basil inhibited
CYP2B6-mediated metabolism of efavirenz and formation of
rifampicin metabolite. There was an increase in rifampicin
metabolite formation against the aqueous at extract both
concentrations (170% at 200 mg/ml), which could be due to the
mechanism of enzyme activation due to the presence of multiple
binding sites at the active site of the enzyme (Atkins et al., 2001;
Tracy, 2006); such activations being concentration-dependant.
The methanolic extract was strong inhibitor of both pathways,
whereas the ethanolic extract was a potent inhibitor of rifampicin
pathway with an IC50 value of 8.94 mg/ml. Nelfinavir was used as
a positive control for this pathway on the assumption that strong
CYP inhibitors could also inhibit b-esterases (Polsky-Fisher
et al., 2006) with an IC50 value of 5.44 mg/ml (9.59 mM). The
ethanolic extract showed strong inhibition activity in a
concentration range from 0-100 mg/ml. At concentrations >100
mg/ml, the IC50 curve did not show a drop in the percentage of
remaining activity, unlike the 2-point screening (percentage
activity drop from 81.7% at 20 mg/ml to 36.97% 200 mg/ml)
indicating the latter to be a relative measurement of the
inhibitory effect of an extract at two different concentrations,
which would not always correlate with the IC50 value obtained.
For the positive control ticlopidine the IC50 value obtained was
within the range reported in earlier studies (12.4–55 mM)
(Hagihara et al., 2008; Choi et al., 2011). For nelfinavir theFrontiers in Pharmacology | www.frontiersin.org 15IC50 was slightly higher than a value of 2.7 mM reported in a
previous HLM study done using different assay conditions and
bilirubin as the substrate (Zhang et al., 2005). The aqueous and
methanolic extracts had strong TDI effect on CYP2B6, the latter
with shift-fold >7; this effect may be attributed to the formation
of reactive secondary metabolites on preincubation with
NADPH. The methanolic extract showed weaker TDI on
esterase pathway at higher concentration, which could possibly
be attributed to the formation of secondary metabolites at higher
concentrations, having the potential to interfere with the binding
of the active principle in the extract with the enzyme, reducing
the TDI effect (Fowler and Zhang, 2008).
The standard deviation (standard error of the mean) for the data
points for few extracts showed high variance in the assays, which
could be attributed to external factors that might have interfered
with the assays, or the loss of metabolite due to degradation, during
the prolonged HPLC runs. All the assays performed were in vitro;
however in an in vivo scenario there are other factors to consider
such as concentration differential between tissues, presence of
natural barriers such as varying capillary bed permeability, the
epithelial membrane barrier, sub-epithelial blood flow, GIT transit
time, disease state and dosage form, and intestinal pH (Gavhane and
Yadav, 2012; Fasinu et al., 2014).
CYP3A4 is induced more efficiently compared to the other
isoenzymes, and is an important criterion for selection in
induction screening studies (Denison and Whitlock, 1995;
Dogra et al., 1998); CYP2B6 has gained recent importance in
clinically significant risk assessment induction in vitro studies on
cryopreserved human hepatocytes, along with CYP3A4 (Fahmi
et al., 2016). In this study, all basil extracts moderately induced
both the CYPs, more effectively activating the mRNA expression
in CYP2B6 in HepG2 cells. O.basilicum was previously reported
in a study on CYP isoenzymes, as an inhibitor of CYP3A4
(Nguyen et al., 2014). In this study, the basil extracts inhibited
CYP3A4 in liver microsomes, and moderately induced mRNA
expression in CYP3A4, especially the ethanolic extract. This
could be due to the synergist ic effects of various
phytoconstituents in the extract, or some other potential
unidentified inducer molecule within the extract, causing
CYP induction.A B
FIGURE 10 | Graphs of the herbal extracts and their fold responses for CYP3A4 and 2B6 mRNA expression, relative to cell control (CC); rifampicin (RIF) and
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B
FIGURE 11 | (A) LC-MS chromatogram of basil extracts in negative mode scan for time duration of 29 min. (B) LC-MS chromatogram of basil (ethanol extract) in
negative mode scan for time duration of 29 min, LC-MS spectra focusing on rosmarinic acid [m/z 359.0764 (M-H)-].
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FIGURE 12 | Chemical structures of the main compounds identified from crude herbal extracts of O.basilicum: (A) Rosmarinic acid; (B) Salvigenin; (C) Tartaric acid;
(D) Isocitric acid; (E) Caftaric acid; (F) Rutin; (G) Eupatorin; and (H) 2,6-Pyridinedicarboxylic acid, nonyl phenethyl ester.
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SL
No.
RT (min) M-H [M-H]– MS/MSc Tentative ID# Type of Compound
BasilAq
1 21.65 359.0764 C18H15O8 161, 133, 135, 179, 197 Rosmarinic acid Phenolic acid
2 1.75 149.0076 C4H5O6 113, 130.997, 141 Tartaric acid Organic acid
3 3.86 191.0175 C6H7O7 111, 129, 173 Isocitric acid Citric acid
4 24.36 327.2150 C18H15O6 116.9, 205, 215, 277, 311 Salvigenin (5-Hydroxy-6,7,4′-trimethoxyflavone) Flavones
5 10.59 311.0392 C13H11O9 135, 149, 179, 311 Caftaric acid
(Caffeoyl-tartaric acid)
Non-flavanoid phenolic
8 16.22 225.1110 C12H17O4 112, 135, 161, 192, 203, 216 12-hydroxyjasmonic acid Carboxylic acid
6 18.23 473.0708 C22H17O12 135, 149, 179, 293, 311 Chicoric acid
(dicaffeoyl-tartaric acid)
Hydroxycinnamic acid
7 23.38 717.1448 C36H29O16 243, 343, 519 Unknown –
BasilMeOH
1 21.61 359.0764 C18H15O8 161, 133, 135, 179, 197 Rosmarinic acid Phenolic acid
2 1.79 341.1076 C12H21O11 89, 173 Dihexose Sugar
3 24.36 327.2150 C18H15O6 116.9, 205, 215, 277, 311 Salvigenin
(5-Hydroxy-6,7,4′-trimethoxyflavone)
Flavones
4 18.09 609.1499 C27H29O16 151, 255, 271, 300, 301 Rutin
(Quercetin-hexoside-rhamnoside)
Flavonoid
5 14.45 387.1648 C21H23O7 59, 119, 207, 300 Medioresinol Furanoid lignin
6 18.74 463.0882 C21H19O12 89, 151, 255, 271, 300 Isoquercetin (Quercetin-hexoside) Flavonoid
7 23.38 717.1450 C36H29O16 243, 343, 519 Unknown –
8 20.99 137.1212 C9H13O 93, 121 trans-ocimene oxide Monoterpenes
BasilEtOH
1 21.6 359.0764 C18H15O8 161, 133, 135, 179, 197 Rosmarinic acid Phenolic acid
2 9.35 153.4201 C10H17O 79, 93, 109, 127, 137 Linalool
(2,6-Dimethyl-2,7-octadien-6-ol; allo-Ocimenol)
Terpene alcohol
3 24.36 327.2150 C18H15O6 116.9, 205, 215, 277, 311 Salvigenin
(5-Hydroxy-6,7,4′-trimethoxyflavone)
Flavone
4 14.76 431.1907 C21H19O10 153, 205, 269, 354, 385 Apigenin-7-O-glucoside Flavonoid glycoside
5 13.82 179.0330 C9H7O4 135 Caffeic acid Hydroxycinnamic acid
6 24.43 329.2310 C18H33O5 171, 211 Trihydroxy octadecenoic acid Fatty acid
7 21.15 187.0944 C9H15O4 125, 158, 169 Eucommiol Cyclopentene dimethanol
8 16.19 225.1113 C12H17O4 112, 135, 161, 192, 203, 216 12-hydroxyjasmonic acid Carboxylic acid
9 18.71 463.0874 C21H19O12 89, 151, 255, 271, 300 Isoquercetin
(Quercetin-hexoside)
FlavonoidFrontiers in Pharmacology | www.frontiersin.org 17 April 2020#References – Hossain et al., 2010; Mena et al., 2012; Simirgiotis et al., 2015; Chen et al., 2016; Stander et al., 2017; Said et al., 2017; https://www.ncbi.nlm.nih.gov/pccompound;
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Kumar et al. Herb-Drug Interaction of Ocimum basilicumLC-MS (positive and negative modes) was used to identify the
flavonoids, polyphenols, and carboxylic acids in the extracts; these
were relatively quantified (reasonable approximations of the relative
amounts of the identified compounds present in each extract) using
calibration curves set up for quercetin and gallic acid (Bhandari and
Rajbhandari, 2015; Punyasiri et al., 2015). Rosmarinic acid was a
major polyphenol identified; a major component in the aromatic
basil essential oil (Kiferle et al., 2011; Güez et al., 2017) and a
potential inducer of CYPs such as CYP1A, 2B, and 3A (Cho and
Yoon, 2015). Other major compounds included salvigenin,
eupatorin, isocitric, tartaric, chicoric and caftaric acids, the
flavonoid rutin, and apigenin-7-O-glucoside, which could have
caused the observed inhibition of CYP2B6 and b-esterase activity.
Salvigenin was previously reported as a moderate inhibitor of
CYP3A enzymes (Quintieri et al., 2008). Caftaric and chicoric
acids in Echinacea, rutin and apigenin derivatives have been
reported to interfere with CYP3A4 activity (Bossaer and Odle,
2012; Cichello et al., 2016; Karakurt, 2016; Tang et al., 2017).
Eupatorin inhibits CYP1A2 (Pan et al., 2014) and the in vitro
proliferation of MDA-MB-468 human breast cancer cells that
express CYP1A1 (Androutsopoulos et al., 2008). High
concentrations of eupatorin, salvigenin and caffeic acids were
observed in the ethanolic extract, potentially attributing to its
strong inhibition of the rifampicin pathway, compared to the
aqueous and methanolic extracts. 12-hydroxyjasmonic acid and
fukugetin were the other major identified compounds, which could
have added to the inducing capabilities of basil extracts on CYP3A4
mRNA expression along with rosmarinic acid (Son et al., 1998; Cho
and Yoon, 2015). The calibration curve set up for gallic acid and
quercetin was in the range of 6.25-200 mg/L; however some of the
identified compounds within the extracts have values above of the
range of the calibration curves. The concentrations calculated for
these compounds are reasonable approximations of the relative
amounts, in comparison to the standard calibrators, and are not
absolute quantifications (Al Feteisi et al., 2015). Various classes of
compounds detected are likely to ionize in the MS to vastly differentFrontiers in Pharmacology | www.frontiersin.org 18degrees, when compared to the standard calibrators; fold-variations
can thus occur in peak areas of these compounds.
As per the FDA guidelines of using model-based predictions
(F.D.A., 2017) to determine drug interactions, basic to highly
dynamic mechanism-based models including physiologically-
based pharmacokinetic (PBPK) models have been used to
predict DDI in various clinical studies. In this study a basic
model was deployed, where GIT concentrations and hepatic
blood concentrations were estimated based on single
recommended dosages of herbal extracts on the assumption of
equal distribution across the entire GIT system. However, factors
such as intestinal fluid composition, dosage form, GIT transit
time, capillary bed permeability, intestinal pH, tissue distribution
and membrane barriers can affect the distribution of the extracts
within the human body (El-Kattan and Varma, 2012; Gavhane
and Yadav, 2012). The AUCR of the target drug, along with
many other factors and parameters such as first order absorption
rate Ka, fraction of systemic clearance of the substrate Fm, the
fraction absorbed after oral administration Fa, the fraction
available after intestinal metabolism Fg, the elimination rate
and the intrinsic clearance CLint were not considered as part of
this prediction model. In this study, the predicted percentile of
inhibition for the aqueous, methanolic and ethanolic extracts
were > 90% against CYP2B6 and rifampicin pathway, however
more mechanistic-dynamic models have to applied considering
all the above parameters to predict the probability of in vivo HDI
of these extracts in the gut assuming that the entire soluble
extract interacts with the intestinal CYP enzymes, and
competitive inhibition characteristics (F.D.A., 2017; Kumar
et al., 2018).CONCLUSIONS
The biochemical phytoprofiling of basil extracts showed the
presence of bioactive compounds that had the potential toTABLE 7 | Secondary metabolites/compounds detected in O.basilicum extracts in positive scan mode in LC-MS/PDA.
SL
No.
RT (min) M+H [M+H]+ MS/MSc Tentative ID# Type of compound
BasilAq
1 10.63 398.2331 C24H32NO4 149, 240, 266 2,6-Pyridinedicarboxylic acid, nonyl phenethyl ester Carboxylic acid
2 7.74 304.3008 C21H38N 91, 212 Pyridine/Amine complex Secondary Metabolites
3 12.28 411.2662 C30H35O 175, 283, 355 Unknown –
4 6.91 311.2210 C18H31O4 96, 149, 219, 275 Furan-2(3H)-one complex Aromatic lactone
5 9.06 399.2498 C25H35O4, C18H39O9 221, 324 Unknown –
BasilMeOH
1 7.32 329.1014 C18H17O6 133, 268 Salvigenin (5-Hydroxy-6,7,4′-trimethoxyflavone) Flavones
2 10.63 398.2324 C24H32NO4 149, 240, 266 2,6-Pyridinedicarboxylic acid, nonyl phenethyl ester Carboxylic acid
3 7.74 304.2997 C21H38N 91, 212 Pyridine/Amine complex Secondary Metabolites
4 6.42 345.0979 C18H17O7 182, 240, 312, 315 Eupatorin (3′,5-Dihydroxy-4′,6,7-trimethoxyflavone) Flavones
BasilEtOH
1 7.32 329.1023 C18H17O6 133, 268 Salvigenin (5-Hydroxy-6,7,4′-trimethoxyflavone) Flavones
2 6.42 345.0959 C18H17O7 182, 240, 312, 315 Eupatorin (3′,5-Dihydroxy-4′,6,7-trimethoxyflavone) Flavones
3 7.16 445.2117 C21H33O10, C32H29O2 105, 194 224, 385, 407 Unknown –
4 10.63 398.2336 C24H32NO4 149, 240, 266 2,6-Pyridinedicarboxylic acid, nonyl phenethyl ester Carboxylic acidApril 2020 | V#References – Ye et al., 2005; Hossain et al., 2010; Čejchanová, 2011; Wang et al., 2012; https://www.ncbi.nlm.nih.gov/pccompound; https://massbank.eu/MassBank/; https://metlin.
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Kumar et al. Herb-Drug Interaction of Ocimum basilicumTABLE 8 | Concentration of each compounds identified within the basil extracts (mg/L equivalents).
# SL No Compound Name Sample name Area RT(min) Conc. units *
(mg/L equivalents of gallic acid/quercetin)
Compound (1) Rosmarinic acid **
1 BasilAq 1699.1760 21.61 2298.037
2 BasilMeOH 1423.3300 21.61 1923.756
3 BasilEtOH 585.0240 21.61 786.304
Compound (2) Tartaric acid
1 BasilAq 593.9001 1.76 798.347
2 BasilMeOH 33.9320 1.76 38.556
3 BasilEtOH 45.3010 1.76 53.982
Compound (3) Isocitric acid
1 BasilAq 742.4790 3.88 999.946
Compound (4) Caftaric acid
1 BasilAq 407.1970 10.60 545.019
Compound (5) Chicoric acid
1 BasilAq 371.2370 18.23 496.228
2 BasilMeOH 22.3180 18.26 22.798
Compound (6) Salvigenin (5-Hydroxy-6,7,4′-trimethoxyflavone) ***
1 BasilAq 430.9610 24.36 73.634
2 BasilMeOH 213.4770 24.36 24.150
3 BasilEtOH 670.6350 24.36 128.167
Compound (7) Rutin (Quercetin-Hexoside-rhamnoside)
1 BasilAq 80.0950 18.07 0.010
2 BasilMeOH 144.1280 18.09 8.371
3 BasilEtOH 146.4550 18.07 8.900
Compound (8) Isoquercetin (Quercetin-Hexoside)
1 BasilMeOH 108.5580 18.73 0.277
2 BasilEtOH 156.3420 18.72 11.150
Compound (9) Linalool (2,6-Dimethyl-2,7-octadien-6-ol)
1 BasilEtOH 133.6801 9.35 5.993
Compound (10) 12-hydroxyjasmonic acid
1 BasilAq 262.7230 16.21 348.991
2 BasilEtOH 255.5850 16.19 339.305
Compound (11) Caffeic acid
1 BasilMeOH 29.9890 13.83 33.206
2 BasilEtOH 433.6770 13.80 580.949
Compound (12) (E)-Fukugetin
1 BasilEtOH 45.8240 26.32 0.005
Compound (13) Medioresinol
1 BasilMeOH 114.7220 14.45 6.020
2 BasilEtOH 69.9301 14.44 0.005
Compound (14) Apigenin-7-O-glucoside
1 BasilMeOH 75.4170 14.77 0.010
2 BasilEtOH 404.7730 14.75 67.675
Compound (15) Trihydroxy octadecenoic acid
1 BasilAq 127.4110 24.44 165.393
2 BasilMeOH 100.3910 24.44 128.731
3 BasilEtOH 396.4770 24.44 530.474
Compound (16) Eucommiol
1 BasilAq 138.4490 21.16 7.078
2 BasilEtOH 354.5340 21.15 56.244
Compound (17) Dihexose
1 BasilMeOH 279.5990 1.8 39.194
Compound (18) Eupatorin (3′,5-Dihydroxy-4′,6,7-trimethoxyflavone)
1 BasilAq 44.5180 6.42 22.874
2 BasilMeOH 217.4830 6.42 111.503
3 BasilEtOH 1305.0280 6.42 668.772
Compound (19) Salvigenin (5-Hydroxy-6,7,4′-trimethoxyflavone)
1 BasilAq 75.5380 7.33 38.769
2 BasilMeOH 655.0720 7.32 335.728
3 BasilEtOH 3619.8580 7.32 1854.916Frontiers in Pharmacology | www.frontiersin.org 19*The relatively quantified concentrations are reasonable approximations of the relative amounts of the identified compounds present in each (Bhandari and Rajbhandari, 2015; Punyasiri
et al., 2015) **All the acid compounds are relatively quantified equivalent to the linear curve of gallic acid, ***All the non- acid compounds are relatively quantified equivalent to the linear
curve of quercetin.April 2020 | Volume 11 | Article 517
Kumar et al. Herb-Drug Interaction of Ocimum basilicuminterfere with CYP activity, including phenols, flavonoids,
alkaloids, phenols, glycosides, coumarins, phytosterols, tannins
and saponins. As per the data reported in this study, hot tea
decoction extracts as prepared by the traditional health
practitioners, had less inhibitory effect on CYP2B6 and b–
esterases when compared to the methanolic and ethanolic
extracts. The aqueous and methanolic extracts showed strong
reversible and TDI of CYP2B6 while the methanolic and
ethanolic extracts inhibited rifampicin metabolism, which may
be attributed to the fact that the dried leaves, inflorescence and
seeds of this herb had more phytoconstituents such as flavonoids
and other secondary metabolites in the composition of the
extracts (Fathiazad et al., 2012; Bhuvaneshwari et al., 2016),
that had strong potential to modulate CYP activity (Manikandan
et al., 2007) or cause toxicity (W.H.O. Monographs, 2005;
Rasekh et al., 2012). Previous studies had only reported the
inhibitory effect of the ethanolic extract on CYP3A4.
Previous in vitro studies have shown that NADPH is a not a
prerequisite in the deacetylation process of rifampicin, and the
increased formation of 25-O-desacetyl rifampicin on addition of
NADPH was ascribed to the possible metabolism of rifampicin
by NADPH-dependent CYP enzymes (Benedetti and Dostert,
1994; Jamis-Dow et al., 1997). Both nelfinavir and basil caused
strong TDI of rifampicin pathway when pre-incubated with
NADPH, which suggested that the involvement of other
enzymes such as CYPs in the biotransformation of rifampicin,
since exogenous supply of NADPH was not mandatory in its
deacetylation. In the induction assays in HepG2 cells, the
methanolic extract induced CYP2B6 mRNA expression, while
the ethanolic extract induced CYP3A4, which could be attributed
to the various phytoconstituents in basil such as rutin,
rosmarinic acid and salvigenin (Debersac et al., 2001; Krı̌ž́ková
et al., 2009), and the two different cell systems (HLM and
HepG2). Polyphenolic compounds, flavonoids, terpenes, and
carboxylic acids were the most observed in basil extracts.
Bioassay-guided fractionation, isolation and identification of
the active phytoconstituents in the active extracts and their effect
on CYP2B6, 3A4 ad rifampicinmetabolism would be a critical step
forward. As per the FDA recommendations, analysis of the effects
of basil extracts on CYPs—1A2, 2A6, 2D6, 2C9, 2C8, 2C19, and
2E1 is essential. Clinical testing of basil extracts with new in vitro
models such as “Whole Cell” approach deploying certified human
hepatocytes in sandwich-culture with the drug clearance pathwaysFrontiers in Pharmacology | www.frontiersin.org 20of metabolism and transport, and key regulatory pathways (CAR/
PXR) (Jackson et al., 2017) would also be beneficial in establishing
critical data on the effects of basil on cytochrome P450 for further
in vivo and clinical trial studies.
In conclusion, this study shows that O.basilicum (basil) may
cause HDI in patients treated with other medications
metabolized by CYP2B6 (such as artemisinin, bupropion,
cyclophosphamide, efavirenz, ketamine, and methadone)
(Zanger and Klein, 2013), or with rifampicin. Caution must
therefore be exercised in patients concurrently taking such
medications. This finding is clinically significant, considering
the fact that it is commonly used as herbal tea, as well as a major
ingredient in many food items, herbal formulations and
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